{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:59:49Z","timestamp":1791082789208,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cld.2023.05.004","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T15:39:32Z","timestamp":1688657972000},"page":"877-893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers"],"prefix":"10.1016","volume":"27","author":[{"given":"Lung-Yi","family":"Mak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rex Wan-Hin","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2023.05.004_bib1","unstructured":"The Polaris Observatory Collaborators. CDA Foundation dashboard. Available at: https:\/\/cdafound.org\/premium-dashboard\/. Accessed April 1, 2023."},{"issue":"4298","key":"10.1016\/j.cld.2023.05.004_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1126\/science.325649","article-title":"Australia antigen and the biology of hepatitis B","volume":"197","author":"Blumberg","year":"1977","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cld.2023.05.004_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/v13061124","article-title":"Envelope proteins of hepatitis B virus: molecular biology and involvement in carcinogenesis","volume":"13","author":"Inoue","year":"2021","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.cld.2023.05.004_bib4","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","article-title":"Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers","volume":"67","author":"Pfefferkorn","year":"2018","journal-title":"Gut"},{"issue":"409","key":"10.1016\/j.cld.2023.05.004_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.cld.2023.05.004_bib6","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2023.05.004_bib7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1073\/pnas.88.3.1059","article-title":"The role of envelope proteins in hepatitis B virus assembly","volume":"88","author":"Bruss","year":"1991","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.cld.2023.05.004_bib8","first-page":"3679","article-title":"Hepatitis B envelope antigen increases Tregs by converting CD4+CD25(-) T\u00a0cells into CD4(+)CD25(+)Foxp3(+) Tregs","volume":"20","author":"Tang","year":"2020","journal-title":"Exp Ther Med"},{"issue":"9","key":"10.1016\/j.cld.2023.05.004_bib9","doi-asserted-by":"crossref","first-page":"e44900","DOI":"10.1371\/journal.pone.0044900","article-title":"HBsAg inhibits IFN-alpha production in plasmacytoid dendritic cells through TNF-alpha and IL-10 induction in monocytes","volume":"7","author":"Shi","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cld.2023.05.004_bib10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.22751","article-title":"Hepatitis B virus suppresses toll-like receptor\u2013mediated innate immune responses in murine parenchymal and nonparenchymal liver cells","volume":"49","author":"Wu","year":"2009","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2023.05.004_bib11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/intimm\/dxg117","article-title":"HBsAg\/HLA-A2 transgenic mice: a model for T\u00a0cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection","volume":"15","author":"Loirat","year":"2003","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.004_bib12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus-specific and global T\u00a0cells in patients with chronic hepatitis B virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.05.004_bib13","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.cld.2023.05.004_bib14","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1136\/gutjnl-2020-323300","article-title":"Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B","volume":"70","author":"Svicher","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.004_bib15","doi-asserted-by":"crossref","first-page":"104618","DOI":"10.1016\/j.antiviral.2019.104618","article-title":"Hepatitis B virus replicating in hepatocellular carcinoma encodes HBx variants with preserved ability to antagonize restriction by Smc5\/6","volume":"172","author":"Riviere","year":"2019","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.cld.2023.05.004_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/path.4938","article-title":"Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus","volume":"243","author":"Liu","year":"2017","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.cld.2023.05.004_bib17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2023.05.004_bib18","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/jvh.13095","article-title":"Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval","volume":"26","author":"Mak","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"issue":"3","key":"10.1016\/j.cld.2023.05.004_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.004_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.004_bib21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2023.05.004_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association For The Study Of The","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2023.05.004_bib23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jvh.12211","article-title":"Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients","volume":"21","author":"Hara","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.cld.2023.05.004_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jvh.13237","article-title":"A\u00a0large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance","volume":"27","author":"Ko","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"10","key":"10.1016\/j.cld.2023.05.004_bib25","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-Year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.004_bib26","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.004_bib27","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","author":"Cornberg","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.004_bib28","doi-asserted-by":"crossref","first-page":"104853","DOI":"10.1016\/j.antiviral.2020.104853","article-title":"Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in\u00a0vitro","volume":"183","author":"Boulon","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cld.2023.05.004_bib29","unstructured":"Boulon R, Blanchet M, Vaillant A, Labonte P. The Hsp40 chaperone DnaJB12 is involved in the morphogenesis of HBV spherical subviral particles and is selectively targeted by nucleic acid polymers. presented at: The Liver Meeting 2020, The AASLD annual meeting; 13-16 November, 2020 2020; Digital Experience."},{"issue":"6","key":"10.1016\/j.cld.2023.05.004_bib30","doi-asserted-by":"crossref","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cld.2023.05.004_bib31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1081\/CLT-100100947","article-title":"Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment","volume":"38","author":"Mata","year":"2000","journal-title":"J\u00a0Toxicol Clin Toxicol"},{"key":"10.1016\/j.cld.2023.05.004_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.omtn.2021.12.013","article-title":"Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules","volume":"27","author":"Kao","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cld.2023.05.004_bib33","unstructured":"Gane E, Yuen MF, Jucov A, et\u00a0al. Safety, Tolerability and Pharmacokinetics (PK) of Single and Multiple Doses of ALG-010133, an S-antigen Transport Inhibiting Oligonucleotide Polymer (STOPSTM), for the Treatment of Chronic Hepatitis B. presented at: The International Liver Congress; June 23\u201326, 2021 2021."},{"issue":"12","key":"10.1016\/j.cld.2023.05.004_bib34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2023.05.004_bib35","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2023.05.004_bib36","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1053\/j.gastro.2020.04.020","article-title":"Nucleic acid polymers are effective in targeting hepatitis B surface antigen, but more trials are needed","volume":"158","author":"Durantel","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.05.004_bib37","unstructured":"Vaillant A, Stern C, de Freitas C, et al. Safety and efficacy of REP 2139-Mg in association with TDF in patients with chronic hepatitis delta and decompensated cirrhosis. presented at: The 32 annual meeting of APASL 2023; 15-19 February 2023, Taipei, Taiwan."},{"key":"10.1016\/j.cld.2023.05.004_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.cld.2023.05.004_bib39","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1128\/jvi.63.2.798-808.1989","article-title":"Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus","volume":"63","author":"Salfeld","year":"1989","journal-title":"J\u00a0Virol"},{"issue":"39","key":"10.1016\/j.cld.2023.05.004_bib40","doi-asserted-by":"crossref","first-page":"11525","DOI":"10.1021\/bi0261645","article-title":"Weak protein-protein interactions are sufficient to drive assembly of hepatitis B virus capsids","volume":"41","author":"Ceres","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.cld.2023.05.004_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691766","article-title":"The functions of hepatitis B virus encoding proteins: viral persistence and liver pathogenesis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.004_bib42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virol.2010.07.005","article-title":"Proximity between the cap and 5' epsilon stem-loop structure is critical for the suppression of pgRNA translation by the hepatitis B viral polymerase","volume":"406","author":"Ryu","year":"2010","journal-title":"Virology"},{"issue":"24","key":"10.1016\/j.cld.2023.05.004_bib43","doi-asserted-by":"crossref","first-page":"13812","DOI":"10.1128\/JVI.78.24.13812-13818.2004","article-title":"Hepatitis B virus nucleocapsids formed by carboxy-terminally mutated core proteins contain spliced viral genomes but lack full-size DNA","volume":"78","author":"Kock","year":"2004","journal-title":"J\u00a0Virol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.004_bib44","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1083\/jcb.118.6.1305","article-title":"Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment","volume":"118","author":"Huovila","year":"1992","journal-title":"J\u00a0Cell Biol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.004_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11901-020-00523-z","article-title":"Role of core\/capsid inhibitors in functional cure strategies for chronic hepatitis B","volume":"19","author":"Hui","year":"2020","journal-title":"Curr Hepat Rep"},{"issue":"10","key":"10.1016\/j.cld.2023.05.004_bib46","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1128\/JVI.76.10.4848-4854.2002","article-title":"A\u00a0small molecule inhibits and misdirects assembly of hepatitis B virus capsids","volume":"76","author":"Zlotnick","year":"2002","journal-title":"J\u00a0Virol"},{"issue":"23","key":"10.1016\/j.cld.2023.05.004_bib47","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0409732102","article-title":"A\u00a0heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly","volume":"102","author":"Stray","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cld.2023.05.004_bib48","first-page":"502A","article-title":"ALG-005398 is a potent non-HAP class I HBV capsid assembly modulator that strongly reduces HBsAg levels in\u00a0vivo","volume":"74","author":"Debing","year":"2021","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2023.05.004_bib49","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/cb100275b","article-title":"Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators","volume":"5","author":"Katen","year":"2010","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.cld.2023.05.004_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2018.07.011","article-title":"Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in\u00a0vitro","volume":"158","author":"Corcuera","year":"2018","journal-title":"Antivir Res"},{"issue":"7","key":"10.1016\/j.cld.2023.05.004_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ph15070773","article-title":"Design and synthesis of hepatitis B virus (HBV) capsid assembly modulators and evaluation of their activity in mammalian cell model","volume":"15","author":"Spunde","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.cld.2023.05.004_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.cld.2023.05.004_bib53","doi-asserted-by":"crossref","first-page":"e1006658","DOI":"10.1371\/journal.ppat.1006658","article-title":"HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways","volume":"13","author":"Guo","year":"2017","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.cld.2023.05.004_bib54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2023.05.004_bib55","doi-asserted-by":"crossref","first-page":"S878","DOI":"10.1016\/S0168-8278(20)32197-8","article-title":"Efficacy and safety of GLS4\/ritonavir combined with entecavir in HBeAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study","volume":"73","author":"Zhang","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2023.05.004_bib56","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial","volume":"6","author":"Yuen","year":"2021","journal-title":"The lancet Gastroenterology & hepatology"},{"key":"10.1016\/j.cld.2023.05.004_bib57","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1016\/S0168-8278(22)00964-3","article-title":"Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with\/without Peg-IFN in chronic hepatitis B patients","volume":"77","author":"Hou","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.004_bib58","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2023.05.004_bib59","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA interference as a novel treatment strategy for chronic hepatitis B infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.05.004_bib60","doi-asserted-by":"crossref","DOI":"10.1177\/13596535221127848","article-title":"EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B","volume":"27","author":"Feld","year":"2022","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cld.2023.05.004_bib61","doi-asserted-by":"crossref","unstructured":"Yuen MF, Chuang WL, Peng CY, et al. EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients presented at: Poster presentation at the AASLD The Liver Meeting; November 4-8 2022, 2022. Washington, DC, USA.","DOI":"10.1016\/S0168-8278(22)01995-X"},{"issue":"5","key":"10.1016\/j.cld.2023.05.004_bib62","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2022.05.027","article-title":"Safety and efficacy of vebicorvir administered with entecavir in treatment-na\u00efve patients with chronic hepatitis B virus infection","volume":"77","author":"Sulkowski","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.004_bib63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2022.04.005","article-title":"Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.004_bib64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14728214.2022.2074977","article-title":"Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials","volume":"27","author":"Hui","year":"2022","journal-title":"Expet Opin Emerg Drugs"},{"key":"10.1016\/j.cld.2023.05.004_bib65","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/S0168-8278(20)30790-X","article-title":"Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study","volume":"73","author":"Yuen","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2023.05.004_bib66","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.molmed.2022.06.002","article-title":"New strategies for the treatment of chronic hepatitis B","volume":"28","author":"Mak","year":"2022","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.cld.2023.05.004_bib67","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0168-8278(20)30773-X","article-title":"Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: interim week 24 data","volume":"73","author":"Janssen","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"S1","key":"10.1016\/j.cld.2023.05.004_bib68","doi-asserted-by":"crossref","first-page":"S835","DOI":"10.1016\/S0168-8278(22)01967-5","article-title":"Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B. Poster Presentation (SAT835)","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.004_bib69","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"The lancet Gastroenterology & hepatology"},{"key":"10.1016\/j.cld.2023.05.004_bib70","unstructured":"Hou JL, Niu J, Ding Y, et al. Safety, pharmacokinetics (PK), and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in subjects with HBeAg positive chronic hepatitis B. presented at: Poster presentation at the AASLD The Liver Meeting, November 4-8 2022; 2022. Washington, DC, USA."},{"issue":"2","key":"10.1016\/j.cld.2023.05.004_bib71","first-page":"64","article-title":"Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses in\u00a0vitro and in humanized mice","author":"Amblard","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl1","key":"10.1016\/j.cld.2023.05.004_bib72","first-page":"S248","article-title":"ABI-4334, a novel hepatitis B virus core inhibitor, accelerates capsid assembly and inhibits cccDNA formation via multiple pathways","volume":"76","author":"Unchwaniwala","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.004_bib73","article-title":"Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: a randomized, placebo-controlled phase 1 study","author":"Agarwal","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.cld.2023.05.004_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11901-022-00590-4","article-title":"Novel combination strategies with investigational agents for functional cure of chronic hepatitis B infection","volume":"21","author":"Hui","year":"2022","journal-title":"Curr Hepat Rep"},{"issue":"5","key":"10.1016\/j.cld.2023.05.004_bib75","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.004_bib76","unstructured":"George J, Stefanova-Petrova D, Antonov K, et\u00a0al. Evaluation of the vebicorvir, NrtI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: Interim analysis from an open label Phase 2 study presented at: Presentation at the AASLD The Liver Meeting, November 4-8 2022; 2022."}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:25Z","timestamp":1761069685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1089326123000648"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}